What Aseptika does

Aseptika is a Cambridge, United Kingdom-based digital health company founded in 2007 that develops inexpensive home monitoring and treatment management devices for patients with Chronic Obstructive Pulmonary Disease (COPD). The company operates its consumer-facing platform under the Activ8rlives brand (activ8rlives.com) and is led by founder, CEO and Managing Director Kevin Auton. Aseptika is structured as a private for-profit entity operating at very small scale (1-10 employees), and its operating model to date has been sustained by non-dilutive grant funding from SBRI Healthcare — a UK NHS-aligned innovation program — across three disclosed rounds in 2013 ($2.94M), 2016 ($1.06M) and 2022 ($0.62M), totaling approximately $4.63M.

Name

Aseptika

Website

https://activ8rlives.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Aseptika is a Cambridge, UK-based digital health company founded in 2007 by Kevin Auton that develops low-cost home monitoring and treatment management devices for COPD patients, operating at micro-scale with grant-funded R&D via its Activ8rlives platform.

Ownership category

akta.pro rank

Product category

Respiratory Health Monitoring

NAICS

Home Health Care Services (62161), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Services-Home Health Care Services (8082), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking) (HLAHACAI)

akta.pro secondary industries

Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB), Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE), COPD & Chronic Bronchitis Management (HLAKANAE)

Keywords

• COPD home monitoring
• Respiratory health devices
• Remote patient monitoring
• Chronic disease management
• Home healthcare technology

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

Aseptika develops an inexpensive home monitoring device and treatment management software for patients with Chronic Obstructive Pulmonary Disease (COPD). The product integrates hardware respiratory sensors with the activ8rlives digital platform to enable daily home-based monitoring of COPD symptoms and support treatment adherence management for patients and healthcare providers in the United Kingdom.

Differentiator

Problem solved

Functional benefit

Products and services

• COPD Home Monitoring Device An inexpensive home monitoring device for patients with Chronic Obstructive Pulmonary Disease (COPD), enabling daily respiratory health monitoring and supporting treatment management outside of clinical settings. Designed for NHS respiratory care programs and UK patients managing chronic respiratory conditions.
• activ8rlives Treatment Management Platform Digital treatment management platform that supports COPD patients and healthcare providers in tracking respiratory health metrics, medication adherence, and treatment plans. Accessible online via activ8rlives.com.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• AstraZeneca: AstraZeneca has invested in connected inhaler programs (e.g., partnerships with Adherium) for its respiratory portfolio, making it a large incumbent whose smart inhaler efforts overlap Aseptika's COPD monitoring focus.
• ResMed: ResMed acquired Propeller Health and sells broader sleep and respiratory care solutions, making it an incumbent whose connected respiratory platform overlaps Aseptika's home monitoring focus.
• Teva Pharmaceutical Industries: Teva markets Digihaler, a connected inhaler platform with integrated sensors, positioning the pharma major as a broad incumbent competing for the same COPD digital therapy category Aseptika targets.
• GlaxoSmithKline: GSK is a global respiratory pharma leader with connected inhaler and digital health initiatives that compete for the COPD digital management category Aseptika serves.
• Philips Respiratory Care: Philips offers connected respiratory care devices and remote monitoring services for COPD and sleep, positioning it as a broad incumbent in the home respiratory monitoring market.

Direct peers

• Adherium: Adherium develops smart inhaler sensors and respiratory disease management platforms, directly competing with Aseptika in connected COPD and asthma monitoring devices.
• Propeller Health (ResMed): Propeller Health, now owned by ResMed, is a leading digital respiratory health platform offering connected inhaler sensors and COPD/asthma management, the closest direct competitor to Aseptika's offering.

Regional players

• Vivisol: Vivisol is a European home respiratory and sleep therapy provider offering home-based oxygen, CPAP, and chronic respiratory management, comparable to Aseptika's UK-focused COPD home monitoring service.

Emerging players

• Aptar Pharma: Aptar Pharma develops connected inhaler components and drug delivery devices with embedded sensors, an emerging player addressing the same connected respiratory device category Aseptika targets.
• Vitalograph: Vitalograph manufactures respiratory diagnostic and monitoring devices including COPD screening tools, a UK-based niche player with overlapping home respiratory monitoring capabilities to Aseptika.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aseptika